Sept 14 (Reuters) - Eli Lilly and Co said on Monday
its rheumatoid arthritis drug Olumiant helped reduce the time
taken to recover from COVID-19 in hospitalized patients in a
The U.S. drugmaker said the drug, in combination with Gilead
Sciences Inc's remdesivir, met the main goal of
shortening recovery when compared to remdesivir alone.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb